Curacne

Isotretinoin

Method of action: Antiacne, Anti-Inflammatory, Antiseborrheic, Dermatoprotective, Keratolytic, Regenerative

Treatment option: Dermatitis, Perioral Dermatitis, Zits, Seborrheic Dermatitis, Acne Vulgaris

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Curacne

Quick Facts

Property	Description
Active Ingredient	Isotretinoin (13-cis-retinoic acid)
Form	Soft Gelatin Capsule
Pharmacological Class	Systemic Retinoid (Dermatological Drug)
Origin	Synthetic Vitamin A Derivative
General Purpose	Treatment of Severe Acne

What Type of Medicine is Curacne (Isotretinoin)?

Curacne is the prescription-only medicine that contains the active ingredient isotretinoin, classified as a systemic retinoid. The drug is a highly potent synthetic compound, specifically the 13-cis-retinoic acid isomer, which is a structural derivative of Vitamin A. This classification identifies it as a powerful dermatological drug that is absorbed via the oral route to act internally and comprehensively throughout the body. Unlike weaker topical options, a systemic retinoid is reserved for conditions requiring a profound, systemic biological effect on skin function.

Composition and Pharmaceutical Form

Curacne is a single active ingredient product formulated as soft gelatin capsules intended for oral administration. The isotretinoin substance is uniquely suspended in an oily vehicle—which often includes substances like hydrogenated soya oil and beeswax—within the capsule. This lipid-based formulation is crucial because isotretinoin is highly lipophilic (fat-soluble), meaning the oily base maximizes the drug's absorption and systemic bioavailability.

The General Purpose of This Powerful Agent

The primary purpose of Curacne is the sustained clearing of severe forms of acne in older children and adults. This includes aggressive types such as recalcitrant nodular acne and cystic acne in patients, typically adults and children aged 12 years and older, who have been found to be unresponsive to conventional therapy, including long-term systemic antibiotics. Systemic retinoids are used for severe, recalcitrant acne that has not responded to standard treatments. The medicine’s use is reserved for promoting long-term remission by controlling the underlying processes that lead to severe inflammation and the risk of permanent scarring.

Regulatory References

What side effects are possible with Curacne?

Possible Side Effects and Safety Information: Curacne (Isotretinoin)

Curacne, whose active substance is isotretinoin, is associated with a specific and significant safety profile that requires strict adherence to regulatory measures.

Mandatory Safety Restrictions

Curacne is classified as a powerful teratogen (substance causing birth defects). Due to the high risk of severe congenital malformations, miscarriage, and stillbirth, the drug is strictly contraindicated for use during pregnancy and breastfeeding.

For all women of childbearing potential, mandatory compliance with a Pregnancy Prevention Programme (PPP/REMS) is required. This program enforces the use of effective contraception (often two forms) starting one month before treatment, throughout the entire treatment course, and for one month after discontinuation. Monthly pregnancy testing is also typically required.

Patients taking this medication must also not donate blood during treatment and for one month following discontinuation.

Key Adverse Reactions

The most frequent adverse events are dose-dependent and involve mucocutaneous dryness. These are classified as Very Common and include dry skin, chapped lips (cheilitis), dry eyes, dry nasal mucosa, and nosebleeds (epistaxis). Other common effects include joint/muscle pain and temporary hair thinning.

Serious and Clinically Significant Adverse Reactions documented in regulatory sources include:

Psychiatric Disorders: Reports of depression, anxiety, mood alterations, psychotic symptoms, suicidal ideation, and suicide attempts have been noted, primarily in the Rare or Very Rare frequency categories. Patients with a history of depression require careful monitoring.
Hepatotoxicity and Lipid Metabolism: Increases in liver enzyme levels (transaminases) and elevated serum triglycerides (hypertriglyceridemia) are very common and require regular blood monitoring. Severe hypertriglyceridemia carries a risk of potentially fatal acute pancreatitis.
Eye and CNS: Decreased night vision (which may persist after treatment), corneal opacities, and Benign Intracranial Hypertension (Pseudotumor Cerebri) are serious, less common risks.
Severe Skin Reactions: Rare but severe mucocutaneous reactions such as Erythema Multiforme, Stevens-Johnson Syndrome (SJS), and Toxic Epidermal Necrolysis (TEN) have been reported.

Use is also generally not recommended for prepubertal acne or in children under 12 years of age.

Overdose and Emergency Response

Overdose and When to Seek Help

Curacne (isotretinoin) is a derivative of Vitamin A, and an acute overdose of the medication may result in signs and symptoms consistent with acute hypervitaminosis A (Vitamin A intoxication). While overdoses are generally considered to be of relatively low toxicity, they constitute a medical emergency that requires immediate professional evaluation.

Documented Signs and Symptoms of Overdose:

Official regulatory information describes that an acute overdose may present with a cluster of signs primarily affecting the central nervous system, vision, and gastrointestinal system. These symptoms can include:

Severe headache
Nausea and vomiting
Dizziness and drowsiness
Visual disturbances

The signs of an acute overdose are generally reversible and typically resolve spontaneously once the medication is discontinued.

Required Emergency Action

Seek immediate medical attention for any suspected overdose. Emergency medical services or a poison control center must be contacted at once. The recommended management for a Curacne overdose is to follow the standard clinical procedures for treating acute Vitamin A intoxication, which involves supportive care and cessation of the drug.

Therapeutic Uses of Curacne

What Curacne Treats: Main Uses and Benefits

Curacne is a prescription medicine reserved for the therapeutic approach for the most severe forms of acne, generally applied in clinical settings that involve conditions associated with significant symptomatic burden. It is commonly used for severe forms of acne, such as nodular or conglobate acne, or acne that carries a risk of permanent scarring, particularly when these conditions have been resistant to adequate courses of standard therapy with systemic anti-bacterials and topical measures.

Therapeutic Scope and Support

The medicine is applied in addressing the symptom cluster of deep, painful lesions, widespread inflammation, and excessive oil production (seborrhea) that characterizes these aggressive forms. This approach supports patients whose symptoms have been chronic or recurrent. The primary intent is to provide support that assists with easing the overall symptom burden and may help maintain functional stability.

Quick Fact: Symptomatic Support

Property	Description
Primary Indication	Severe, recalcitrant nodular and cystic acne.
Symptom Focus	Deep, painful lesions, extensive inflammation, and seborrhea.
Key Benefit	May assist with easing the risk of permanent scarring and disfigurement.
Use Context	Applied when acne is resistant to standard systemic and topical treatments.

Eligibility and Restrictions for Use

Absolute Contraindications

The medicine is strictly contraindicated and must not be used by women who are pregnant or who may become pregnant, due to the high risk of severe birth defects. It is also contraindicated for breastfeeding women.

Non-eligibility is also defined by pre-existing health conditions, including hepatic insufficiency (liver failure), excessively high blood lipid values, and hypervitaminosis A. Use is also prohibited for patients who have known hypersensitivity to isotretinoin or any of its components, such as soya or peanut derivatives found in some capsule formulations. Patients concurrently receiving tetracycline antibiotics are also strictly contraindicated due to the risk of pseudotumor cerebri.

Age and Conditional Eligibility

Curacne is indicated for adults and adolescents starting at 12 years of age who suffer from severe acne unresponsive to other treatments. Use is not recommended for children under 12, as safety and efficacy have not been established in this age group.

Patients with severe renal insufficiency may be eligible but treatment must be initiated at a lower, specialized dose. Use requires especially careful consideration for patients with conditions such as diabetes, obesity, or lipid metabolism disorder, as these conditions may increase risk during therapy. Females of childbearing potential are eligible only if they adhere to the mandatory requirements of a risk management or prevention programme.

What should I know about interactions with other medicines?

Interaction Scope

Property	Description
Medicinal product categories with documented interactions	Tetracycline-class antibiotics; Vitamin A-containing products; Oral contraceptives; Systemic Corticosteroids; Phenytoin.
Specific interacting medicines (if explicitly listed)	Tetracyclines; Vitamin A and derivatives.
Mechanistic basis of interactions (only if stated in label)	Pharmacodynamic interaction (additive effects); Pharmacokinetic interaction (food-enhanced absorption).
Timing-based interaction rules (if applicable)	Avoid cosmetic procedures (waxing, dermabrasion, laser) during therapy and for at least 6 months after discontinuation.
Population-specific interaction notes (if applicable)	Increased exposure risk in patients with hepatic impairment (due to slower clearance).
Interaction-related restrictions	Co-administration with Tetracyclines is prohibited; Co-administration with Vitamin A supplements is restricted; Use of St. John's Wort is restricted.

Interaction Classifications (High-Level)

Property	Classification
Interaction severity classification (as defined in official documents)	Contraindicated (Tetracyclines); Use with caution/Restricted (Vitamin A, St. John's Wort, Phenytoin, Corticosteroids).
Regulatory basis (EMA / FDA / etc.)	Based on multiple governmental regulatory documents.
Interaction-context constraints (as defined in official documents)	Administration must occur with food (pharmacokinetic requirement); Requires avoidance of specific cosmetic procedures for a defined post-treatment period (procedural constraint).

Resulting Interaction Structure

Official interaction statements:

Co-administration with Tetracycline-class antibiotics is strictly contraindicated due to the documented risk of developing Intracranial Hypertension.
The simultaneous use of Vitamin A supplements is restricted because it poses an additive pharmacodynamic risk of adverse effects characteristic of hypervitaminosis A.
The administration of the medicine with food is required because a high-fat meal significantly increases the systemic exposure (Cmax and AUC) of isotretinoin.
Cosmetic procedures that resurface or remove skin are prohibited during the course of therapy and for a period of at least six months following discontinuation.
Caution is advised for co-use with Phenytoin and Systemic Corticosteroids due to their association with bone loss.
St. John's Wort is restricted due to potential interference with the effectiveness of mandatory oral contraceptives.

Connection to the overall interaction profile (2–4 sentences): The regulatory documents establish the interaction profile by defining a core contraindicated combination (Tetracyclines) and mandatory requirements, such as co-administration with food to optimize systemic exposure. The profile also restricts co-use with substances that present additive toxicity risks (Vitamin A) and defines restrictions on specific cosmetic procedures and supplements (St. John's Wort).

Mechanism of Action

Curacne's mechanism involves multi-pronged actions, resulting in a reduction in sebaceous gland size and activity. The primary action involves binding to the retinoic acid receptor (RAR), a nuclear receptor. This binding event modulates gene transcription, specifically downregulating the expression of Toll-like receptor 2 (TLR2), which mediates inflammation.

A secondary effect is the direct inhibition of Propionibacterium acnes (P. acnes) proliferation. This inhibition is achieved by reducing the availability of sebaceous lipids, which are the primary nutrient source for the bacteria. Furthermore, Curacne modulates the skin's barrier function, reducing trans-epidermal water loss. The cumulative mechanistic effect is a normalization of epithelial differentiation and a reduction in inflammatory responses.

Dosage and Administration Information

Curacne (isotretinoin) is a retinoid capsule taken orally according to a precise regimen based on body weight, intended to be used for a defined course of therapy. Strict adherence to the official administration instructions is mandatory.

Official Administration Guidelines

Administration Component	Regulatory Instruction
Route of Administration	Oral (by mouth)
Dosing Schedule	Initial daily dose is typically 0.5 to 1 mg/kg/day. For very severe disease (e.g., scarring or extensive trunk involvement), the dose may be increased up to 2 mg/kg/day as tolerated.
Frequency and Timing	The total daily dose is usually administered in two divided doses.
Administration with Food	The capsules must be swallowed whole with a full glass of liquid and taken immediately with a meal (a high-fat meal is necessary for optimal absorption).
Missed Dose Rule	If a dose is missed, skip that dose and do not take two doses at the same time to make up for the missed one.
Course Duration	A standard course of therapy is typically 15 to 20 weeks. Treatment is generally continued until a target cumulative dose of 120 to 150 mg/kg has been achieved.
Retreatment Interval	If a second course of therapy is needed, it should not be initiated before a two-month waiting period, as improvement may continue during this time.

Special Procedural Requirements

Curacne must be administered as part of a formal Risk Evaluation and Mitigation Strategy (REMS), such as the iPLEDGE program in the US, or a Pregnancy Prevention Programme in Europe, for all individuals who can become pregnant. Furthermore, patients with severe renal impairment must be started on a lower initial daily dose (e.g., 10 mg/day) and the dose adjusted as tolerated.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Curacne

Evidence for use in Severe Nodular Acne

Curacne has been studied for severe nodular acne, which is a condition involving periods of heightened symptoms. The research primarily includes randomized controlled trials (RCTs) and various observational settings. These studies typically examined populations of adolescents and adults who had severe, resistant acne that had not adequately responded to other treatments. Researchers monitored several outcomes, including measures related to physical discomfort, the number of lesions, and standardized evaluations of skin characteristics over the study period.

The findings describe patterns observed in the studies, which explored short-term symptom changes. These studies report how symptoms evolved in the observed populations over defined time intervals. However, the results apply only to the populations studied, and individual outcomes can vary. The research contributes insight into short-term changes and helps contextualize how patients reported their experience during the trials.

Evidence for use in Other Forms of Severe Acne

Research has also explored the use of Curacne in individuals with other forms of severe, resistant acne. These studies examined populations facing conditions characterized by cycles of stability and flare-ups, focusing on outcomes linked to inflammatory or irritative states. These findings indicate patterns related to measures of symptom intensity and variability, particularly in conditions involving periods of heightened symptoms.

What is Still Uncertain About Curacne

Research is subject to limitations, including that sample sizes were modest in some specialized studies, meaning that the overall body of evidence for these indications is limited and heterogeneous. A major gap is the lack of information for long-term outcomes, as long-term study observations are not fully established. Follow-up durations were limited or inconsistent across the various types of studies, and data for certain groups remain insufficient. The existing body of evidence highlights what is known—and what is still uncertain.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Curacne (FAQ)

Q: Is it normal to experience a 'purge' or initial breakout when starting Curacne?

Official patient information notes that the acne may temporarily worsen, sometimes described as a 'flare-up,' during the initial weeks of treatment. This is typically temporary. Patients are advised to report a severe or persistent flare-up to the prescriber who manages their treatment.

Q: What should I do if my side effects from Curacne seem severe?

Regulatory guidance indicates that if signs of severe side effects occur (e.g., severe headache, vision changes, signs of liver injury like yellowing skin, or severe stomach pain), stopping the medication may be required, and immediate medical attention or contact with the prescribing doctor is necessary.

Q: Can men use Curacne and what are their specific risks?

Yes, men can use this medicine for severe acne. Official regulatory information notes that men are not subject to the mandatory Pregnancy Prevention Programme required for women. While small amounts of the active ingredient are found in semen, regulatory documents indicate that there has been no known adverse effect on the fetus or pregnancy when a man fathers a child while on the medicine.

Q: Does Curacne interact with common pain relievers like ibuprofen?

Regulatory documents do not list common, non-prescription pain relievers like ibuprofen as a substance with a documented interaction or restriction. However, the product information cautions about co-use with other specific drug classes. It is important that all medicines and supplements, even common ones, be disclosed to a prescriber before or during treatment.

Q: Does Curacne affect how well I heal from cuts or wounds?

Official safety guidance advises that the skin may become more delicate while taking this medicine, which may cause wounds, cuts, or abrasions to take longer to heal. Due to this, cosmetic procedures that resurface or remove skin, such as waxing, dermabrasion, or laser treatments, are required to be avoided during therapy and for a defined period afterward.

Q: Is it possible to have an allergic reaction to Curacne?

Yes, serious allergic reactions (hypersensitivity) are noted in regulatory safety information. The medicine is contraindicated (must not be used) for patients with a known hypersensitivity to the active ingredient or to any of its capsule components. Immediate medical attention is necessary if signs of a severe allergic reaction develop.

Q: Does sun exposure while on Curacne increase the risk of skin cancer?

Regulatory documents strictly require patients to avoid intense sun exposure and UV light sources, such as sunbeds, due to increased skin sensitivity. The guidance focuses on the requirement to avoid UV light and the use of sun protection, highlighting the importance of minimizing UV damage while on the medicine.

Q: What happens after the treatment course of Curacne is finished?

The treatment course is usually considered finished once a target cumulative dose is reached. Further improvement in the acne may continue to be observed for up to two months after the medicine is stopped. Certain safety restrictions, such as avoiding pregnancy and cosmetic procedures, are required to be continued for a defined period after discontinuation, as outlined in official guidelines.

Q: Is acne likely to come back after stopping Curacne?

Official information indicates that a single course of treatment achieves a sustained clearing of acne for the majority of patients. While a definite relapse is possible for some individuals, the guidance states that if a second course is needed, it should only be considered after a waiting period of at least eight weeks.

Q: How long do you have to wait to start a second course of Curacne?

Regulatory guidance requires that a second course of treatment, if needed, should not be considered until at least eight weeks have passed since the end of the first course. This waiting period is mandatory because improvement in your acne may continue during that time.

Q: Does Curacne help with acne scarring?

The medicine is officially indicated for the treatment of severe acne, specifically for forms that are 'at risk of permanent scarring.' Its use is intended to prevent new scarring by controlling the underlying severe inflammatory condition, but the drug is not listed as a treatment for existing scars.

Q: What foods should be avoided when taking Curacne?

Regulatory guidance focuses on the restriction or avoidance of Vitamin A supplements, due to the additive risk of excessive Vitamin A (hypervitaminosis A) symptoms. Otherwise, no specific foods are prohibited, but it is required that the medicine be taken with a meal (preferably high-fat) for optimal absorption.

Q: Are there long-term health risks associated with taking Curacne?

Regulatory safety reviews have specifically investigated reports of certain adverse effects, such as psychiatric and sexual disorders, which have been reported to persist after the medicine has been stopped. The overall benefit/risk balance remains favorable for severe acne, but any persistent side effects should be discussed with the treating prescriber.

Q: What level of severity must acne be to qualify for Curacne treatment?

Official prescribing information states that the medicine is reserved for severe forms of acne, such as nodular or conglobate acne, or acne that is clearly at risk of permanent scarring. These are forms that are resistant to adequate courses of standard treatments, including systemic anti-bacterials and topical therapies.

Q: Is Curacne prescribed for blackheads and whiteheads only?

No, official prescribing information indicates the medicine is reserved for severe forms of acne (such as deep or multiple pus-filled spots, nodules, or cysts). Blackheads and whiteheads (comedones) are typically treated with milder, topical medicines and are not the primary indication for this powerful systemic treatment.

Q: Can Curacne cause headaches or migraines?

Yes, headaches are listed in regulatory documents as a common side effect. Importantly, the medicine carries a serious but less common risk known as Benign Intracranial Hypertension (Pseudotumor Cerebri), which is characterized by severe, persistent headaches and requires immediate medical attention.

Q: Is Curacne a type of antibiotic?

No, Curacne is classified as a systemic retinoid, which is a derivative of Vitamin A, not an antibiotic. While its mechanism does help reduce the proliferation of the acne-causing bacteria (P. acnes) by reducing their nutrient source, its primary action is regulating skin cell growth and oil gland activity.

Q: Is hair thinning a possible side effect of Curacne?

Regulatory information lists temporary hair thinning as a common side effect of treatment. Patients often ask if this effect can be permanent; official documentation focuses on the effect being temporary and dose-dependent, and any concerns can be addressed by the treating prescriber.

Q: Can Curacne affect your mood or cause depression?

Yes, official safety warnings mention reports of psychiatric disorders, including depression, anxiety, mood alterations, and, rarely, suicidal ideation. Patients with a history of depression or mood disorders must be monitored carefully throughout treatment. Patients are advised that any changes in mood or behavior should be reported to the prescriber.

Q: Are the side effects of Curacne permanent?

Most common side effects, such as dry skin and lips, are dose-dependent and expected to resolve after treatment is stopped. However, serious adverse effects, such as decreased night vision or certain psychiatric symptoms, have been reported in safety reviews to persist in some individuals after discontinuation. Any persistent side effects should be discussed with the treating prescriber.

Q: How soon after stopping Curacne can a woman safely become pregnant?

Women of childbearing potential are required to continue effective contraception for at least one month after the medicine has been stopped. This requirement is a mandatory part of the Pregnancy Prevention Programme to ensure the drug is cleared from the body before conception can safely occur.

Q: Can Curacne be used to treat body acne?

Yes, the medicine is indicated for severe forms of acne that are resistant to other therapies. The official administration guidelines acknowledge its use in cases of severe disease with 'extensive trunk involvement,' indicating that body acne, particularly on the chest and back, is an area that this medicine may be prescribed to treat.

Q: What is the typical 'maximum dose' of Curacne?

The dose is determined on an individual basis by a prescriber. Regulatory guidance notes that for very severe or extensive disease (such as severe trunk involvement), the dose may be increased up to 2 mg/kg/day as tolerated by the patient. The total treatment goal is to reach a specified cumulative dose.

How should Curacne be stored and disposed of?

Official Storage Requirements

Curacne (isotretinoin) must be stored strictly according to the conditions defined in official regulatory labeling to ensure its stability and safety. The medication requires storage at room temperature, typically specified as not above 25 C.

It is essential to keep the capsules in the original container and the outer carton to protect them from light and moisture. The container must be kept tightly closed and stored in a location safely out of the sight and reach of children.

Official Disposal Rules

Unused or expired Curacne should not be disposed of in household garbage or flushed down a sink or toilet (wastewater). Official disposal instructions require patients to return any unused capsules to a pharmacist for controlled destruction. This controlled process prevents environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.